In recent years, the treatment of many patients with non-small-cell
lung cancer (NSCLC) has evolved into a multidisciplinary effort combining
the talents of medical oncologists, radiation oncologists, and thoracic
surgeons. Prospective, randomized trials have demonstrated improved survival
rates in patients with locally advanced disease who are treated with cisplatin
(Platinol)-based induction chemotherapy prior to radiation therapy[1,2]
or surgery.[3,4] However, interpretation of these and other studies and
application of the findings to the management of an individual patient
require a thorough understanding of prognostic factors and staging.
Weight loss, performance status, age, gender, serum lactate dehydrogenase
level, and disease stage are all known prognostic factors for patients
with NSCLC. Pulmonary function and the presence of significant heart,
lung, or other medical disease must be carefully considered prior to initiating
multimodality therapy. In general, multimodality trials have enrolled patients
with good prognostic features who were eligible to receive high-dose cisplatin
chemotherapy and undergo thoracic surgery.
The importance of rigorous staging cannot be overemphasized. Particular
attention must be paid to the supraclavicular (N3) and cervical (M1) lymph
node regions on examination. In addition to routine serum and hematologic
testing, an assessment of cardiopulmonary function, including pulmonary
function tests with spirometry and measurements of diffusing capacity and
arterial blood gases, is required. All patients should undergo a CT scan
of the chest and upper abdomen, including the adrenal glands.
The routine use of brain and bone scans in patients with clinical stage
I or II disease is controversial, but these imaging studies should be performed
if clinically indicated. Patients who appear to have stage III disease
should routinely undergo brain and bone imaging, as there is a greater
likelihood of metastatic spread in this group. In patients who appear to
have locoregional disease spread on CT scan, further evaluation of the
mediastinum via bronchoscopy and mediastinoscopy, mediastinotomy, fine-needle
aspiration, or video-assisted thora- coscopy provides essential information
for proper staging and treatment selection.
Stages I and II NSCLC
In a series of 598 resected stage I NSCLC patients from Memorial Sloan-Kettering
Cancer Center, the 5-year survival rate was 82% in patients with
T1 N0 disease, as compared with 68% in patients with T2 tumors. Despite
complete resection, 50% of the 62 patients who underwent wedge resection
or segmentectomy had a recurrence.
This finding is similar to the results of the Lung Cancer Study Group
(LCSG) trial, which randomized T1 N0 patients to lobectomy or limited resection
(segmentectomy or wedge resection). This trial found a significant increase
in local recurrence and a decreased survival rate following limited resection.
Given these findings, it seems unwise to pursue thoracoscopic resection
for patients with T1 N0 disease.
The rate of second primary cancers after resection of stage I NSCLC
is very high; fully one-third of patients from the Memorial Sloan-Kettering
series developed second primaries. Given these findings, resected stage
I patients should be encouraged to participate in chemoprevention trials.
Patients with stage II (T1-2 N1) disease represent about 10% of all
patients with NSCLC and have a 5-year survival rate of 39% following surgery.
Because of the poor prognosis of patients with relatively early-stage disease,
research has focused on adjuvant therapies.
Trials of postoperative adjuvant therapy for early NSCLC have yielded
mixed results, although the majority of trials have been negative. A recent
Japanese trial found that NSCLC patients (the majority of whom were stage
I) randomized to receive oral tegafur (Ftorafur) plus uracil for 1 year
after surgery had improved survival compared to those who received no further
treatment. Currently, the National Cancer Institute of Canada is conducting
a trial comparing four courses of vinorelbine (Navelbine) and cisplatin
to no additional treatment in patients with completely resected T2 N0 or
T1-2 N1 NSCLC. In this study, tissue is also being collected to develop
a large tumor bank. This should facilitate identification of important
biologic prognostic factors that may allow for selection of appropriate
candidates for adjuvant therapy in the future.
Induction chemotherapy with paclitaxel (Taxol) and carboplatin (Paraplatin)
is currently under investigation in the Bimodality Lung Oncology Team (BLOT)
trial. This trial is ongoing at seven major cancer centers across the United
States.* The protocol calls for perioperative chemotherapy (two induction
and three postoperative cycles) for clinical T2 N0, T1-2 N1, or T3 N0-1
NSCLC. Eligible patients must have a negative mediastinoscopy. This is
the first trial to employ induction chemotherapy for "early"-stage
Given the potential morbidity of chemotherapy and the preponderance
of negative data from the randomized adjuvant chemotherapy trials completed
to date, "standard" treatment of stage I and II NSCLC remains
surgery alone. Results of trials employing newer-generation chemotherapy
regimens in the preoperative and postoperative setting are anxiously awaited.
Stage III NSCLC
As discussed by Greco and Hainsworth, patients with stage IIIA NSCLC
are a very heterogeneous group. At the more favorable end of the spectrum
are patients with T3 N0-1 disease. Following surgical resection, these
patients have 5-year survival rates of 40% to 50% (N0) or 20% (N1). Many
such patients were included in the randomized perioperative chemotherapy
trials of Roth et al and Rosell et al.[3,4] Both of these trials found
significantly improved survival rates among patients who received chemotherapy
and surgery compared with those who received surgery alone.
The outcome for patients with "minimal N2" disease (intranodal
involvement of a single ipsilateral mediastinal lymph node) found at thoracotomy
depends on T-stage; patients who have T1 or T2 primary tumors fare better
than those who have T3. Minimal N2 disease is relatively uncommon (10%
to 20% of IIIa NSCLC) and is usually discovered at the time of thoracotomy.
Patients with this presentation usually undergo resection that includes
a complete mediastinal lymph node dissection and have a 5-year survival
rate of 30%.
The optimal treatment of patients with multiple levels of N2 (nonbulky)
nodal involvement is in evolution. It is clear that single-modality treatment
with surgery or radiation alone affords little chance for long-term survival.
Many phase II trials have demonstrated improved response, resection, and
survival rates with induction chemotherapy or chemoradiotherapy before
surgery. Other investigators have treated similar patients with chemotherapy
and radiation given either concomitantly or sequentially (without surgery).
The results of these trials have been strikingly similar, with most reporting
long-term survival rates in the range of 20%.
At present, it is not known whether surgery or irradiation is the optimal
"adjuvant" to chemotherapy or whether "trimodality"
therapy is better than "bimodality" therapy. Moreover, the value
of additional chemotherapy cycles after surgery or irradiation has not
been established. It is noteworthy that patients who achieve a pathologic
complete response following induction chemotherapy enjoy the best chance
for long-term survival. Given that the majority of patients die of
systemic disease, only improvements in systemic therapy will likely lead
to meaningful increases in long-term survival.
Patients with multiple bulky ipsilateral nodes or extracapsular spread
(the least favorable IIIA presentation) or those with contralateral mediastinal
or hilar nodal disease, supraclavicular nodal involvement, or direct mediastinal
invasion (IIIB disease) should be offered combined-modality therapy with
chemotherapy and irradiation. Trials currently underway are exploring refinements
in radiotherapy (dose delivery and fractionation), chemotherapy/radiation
interactions (sequential vs concomitant) and newer chemotherapy combinations.
To date, there is no evidence from randomized trials that radiation given
concomitantly with chemotherapy yields improved survival in patients with
NSCLC. However, there is an increase in treatment-related toxicity with
this approach. Thus, unless future data prove otherwise, the concomitant
use of chemotherapy and radiation therapy for stage III NSCLC is not recommended
outside the context of a clinical trial.
Postoperative mediastinal irradiation has been shown to significantly
reduce the risk of mediastinal relapse but does not have a measurable effect
on survival in patients with resected, node-positive NSCLC. Studies of
postoperative chemotherapy for stage III disease have shown no benefit
on overall survival. The LCSG trials employing cyclophosphamide (Cytoxan,
Neosar), doxorubicin, and cisplatin chemotherapy after surgery did not
show a significant improvement in overall survival.[12,13] Similarly, trials
conducted at Memorial Sloan-Kettering Cancer Center and in Japan
found no benefit of postoperative high-dose cisplatin and vindesine (Eldisine)
Finally, patients with malignant pleural effusions (T4) should not be
considered for combined-modality therapy, as their prognosis mirrors that
of patients with metastatic disease.
As reviewed by Greco and Hainsworth, a number of new chemotherapeutic
agents that hold promise for the treatment of patients with stage IIIB
and IV NSCLC have been identified recently. New chemotherapy combinations
of paclitaxel/cisplatin, paclitaxel/carboplatin, and vinorelbine/cisplatin
appear to be superior to etoposide (Etopophos/VePesid)/cisplatin. Other
combinations incorporating gemcitabine (Gemzar) and topotecan (Hycamtin)
are now being tested. Incorporation of the "new generation" of
chemotherapy into the therapy for NSCLC will hopefully lead to improved
survival for all patients with this disease.
1. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage
III NSCLC: Seven year follow-up of CALGB 8433 trial. J Natl Cancer Inst
2. Sause WT, Scott C, Taylor S, et al: RTOG 88-08 and Eastern Cooperative
Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in
regionally advanced, unresectable NSCLC. J Natl Cancer Inst 87:198-205,
3. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing
perioperative chemotherapy and surgery with surgery alone in resectable
stage IIIA NSCLC. J Natl Cancer Inst 86:673-680, 1994.
4. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing
preoperative chemotherapy plus surgery with surgery alone in patients with
NSCLC. N Engl J Med 330:153-158, 1994.
5. O'Connell J, Kris M, Gralla R, et al: Frequency and prognostic importance
of pretreatment clinical characteristics in patients with advanced NSCLC
treated with combination chemotherapy. J Clin Oncol 4:1604-1614, 1986.
6. Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence
and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc
Surg 109:120-129, 1995.
7. Ginsberg RJ: The role of limited resection in the treatment of early
stage lung cancer. Lung Cancer 11(suppl 2):35-36, 1994
8. Martini N, Burt ME, Bains MS, et al: Survival after resection of
stage II non-small-cell lung cancer. Ann Thorac Surg 54:460-466, 1992
9. Wada H, Hitomi S, Teramatsu T, et al: Adjuvant chemotherapy after
complete resection in NSCLC. J Clin Oncol 14:1048-1054, 1996.
10. Martini N, Flehinger BJ, Zaman MB, et al: Results of resection in
non-oat cell carcinoma of the lung with mediastinal lymph node metastases.
Ann Surg 198:386-397, 1983.
11. Pisters KMW, Kris MG, Gralla RJ, et al: Pathologic complete response
in advanced non-small-cell lung cancer following preoperative chemotherapy:
Implications for the design of future non-small-cell lung cancer combined
modality trials. J Clin Oncol 11:1757-1762, 1993.
12. Holmes EC, Gail M, and The Lung Cancer Study Group: Surgical adjuvant
therapy for stage II and stage III adenocarcinoma and large cell undifferentiated
carcinoma. J Clin Oncol 4:710-715, 1986.
13. Lad T, Rubinstein L, Sadeghi A, et al: The benefit of adjuvant treatment
for resected locally advanced NSCLC. J Clin Oncol 6:9-17, 1988.
14. Pisters KMW, Kris MG, Gralla RJ, et al: Randomized trial comparing
postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation
with irradiation alone in stage III (N2) NSCLC. J Surg Oncol 56:236-241,
15. Ohta M, Miyazawa N, Watanabe Y, et al: Adjuvant chemotherapy for
completely resected stage III NSCLC: Results of a randomized prospective
study. J Thorac Cardiovasc Surg 106:703-708, 1993.